Effects of intraduodenal glucose and fructose on antropyloric motility and appetite in healthy humans.
Oral fructose empties from the stomach more rapidly and may suppress food intake more than oral glucose. The purpose of the study was to evaluate the effects of intraduodenal infusions of fructose and glucose on antropyloric motility and appetite. Ten healthy volunteers were given intraduodenal infusions of 25% fructose, 25% glucose, or 0.9% saline (2 ml/min for 90 min). Antropyloric pressures, blood glucose, and plasma insulin, gastric inhibitory peptide (GIP), and glucagon-like peptide-1 (GLP-1) were measured concurrently; a buffet meal was offered at the end of the infusion. Intraduodenal fructose and glucose suppressed antral waves (P < 0. 0005 for both), stimulated isolated pyloric pressure waves (P < 0.05 for both), and increased basal pyloric pressure (P = 0.10 and P < 0. 05, respectively) compared with saline, without any significant difference between them. Intraduodenal glucose increased blood glucose (P < 0.0005), as well as plasma insulin (P < 0.0005) and GIP (P < 0.005) more than intraduodenal fructose, whereas there was no difference in the GLP-1 response. Intraduodenal fructose suppressed food intake compared with saline (P < 0.05) and glucose (P = 0.07). We conclude that, when infused intraduodenally at 2 kcal/min for 90 min 1) fructose and glucose have comparable effects on antropyloric pressures, 2) fructose tends to suppress food intake more than glucose, despite similar GLP-1 and less GIP release, and 3) GIP, rather than GLP-1, probably accounts for the greater insulin response to glucose than fructose.
Rayner
C K
CK
University of Adelaide Department of Medicine, Royal Adelaide Hospital, Adelaide 5000, Australia.
Park
H S
HS
Wishart
J M
JM
Kong
M
M
Doran
S M
SM
Horowitz
M
M
D000328:Adult; D001066:Appetite / Q000187:drug effects*; D001786:Blood Glucose / Q000032:analysis; D002404:Catheterization; D004386:Duodenum; D005260:Female; D005632:Fructose / Q000008:administration & dosage* / Q000494:pharmacology; D005749:Gastric Inhibitory Polypeptide / Q000097:blood; D005769:Gastrointestinal Motility / Q000187:drug effects*; D005934:Glucagon / Q000097:blood; D052216:Glucagon-Like Peptide 1; D005947:Glucose / Q000008:administration & dosage* / Q000494:pharmacology; D006801:Humans; D007328:Insulin / Q000097:blood; D007441:Intubation, Gastrointestinal; D008297:Male; D010446:Peptide Fragments / Q000097:blood; D011312:Pressure; D011498:Protein Precursors / Q000097:blood; D011708:Pylorus / Q000187:drug effects*; D012016:Reference Values; D016037:Single-Blind Method
D001786:Blood Glucose; D007328:Insulin; D010446:Peptide Fragments; D011498:Protein Precursors; D005632:Fructose; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D005947:Glucose